{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:03:17Z","timestamp":1791421397672,"version":"4.3.3"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.rmed.2025.108243","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:24:11Z","timestamp":1751545451000},"page":"108243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Targeting neutrophilic inflammation in obstructive airway disease - A narrative review of brensocatib therapy"],"prefix":"10.1016","volume":"246","author":[{"given":"Jyoti","family":"Bajpai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rmed.2025.108243_bib2","first-page":"141","article-title":"Chronic airflow limitation in developing countries: burden and priorities","volume":"2","author":"A\u00eft-Khaled","year":"2007","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108243_bib3","article-title":"The unmet global burden of COPD","volume":"3","author":"Quaderi","year":"2018","journal-title":"Glob. Health Epidemiol. Genom."},{"key":"10.1016\/j.rmed.2025.108243_bib4","article-title":"Bronchiectasis-COPD overlap syndrome: a comprehensive review of its pathophysiology and potential cardiovascular implications","volume":"19","author":"Alam","year":"2024","journal-title":"Ther. Adv. Pulm. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108243_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/diagnostics12051175","article-title":"Neutrophils and asthma","volume":"12","author":"Yamasaki","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.rmed.2025.108243_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.107957","article-title":"Challenges in treating patients with comorbid asthma and bronchiectasis","volume":"238","author":"Cazzola","year":"2025","journal-title":"Respir. Med."},{"issue":"11","key":"10.1016\/j.rmed.2025.108243_bib7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","article-title":"Rethinking bronchiectasis as an inflammatory disease","volume":"12","author":"Long","year":"2024","journal-title":"Lancet. Respir. Med."},{"key":"10.1016\/j.rmed.2025.108243_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pharmthera.2018.05.011","article-title":"Therapeutic targeting of cathepsin C: from pathophysiology to treatment","volume":"190","author":"Korkmaz","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"23","key":"10.1016\/j.rmed.2025.108243_bib9","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1093\/emboj\/20.23.6570","article-title":"Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases","volume":"20","author":"Turk","year":"2001","journal-title":"EMBO J."},{"issue":"16","key":"10.1016\/j.rmed.2025.108243_bib10","doi-asserted-by":"crossref","first-page":"10695","DOI":"10.1074\/jbc.272.16.10695","article-title":"Molecular cloning, chromosomal localization, and expression of murine dipeptidyl peptidase I","volume":"272","author":"Pham","year":"1997","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.rmed.2025.108243_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI0213462","article-title":"Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis","volume":"109","author":"Adkison","year":"2002","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12440","article-title":"Granulopoiesis and granules of human neutrophils","volume":"273","author":"Cowland","year":"2016","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.rmed.2025.108243_bib13","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.V80.8.2012.2012","article-title":"Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products","volume":"80","author":"Colotta","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.rmed.2025.108243_bib14","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","article-title":"The neutrophil's role during health and disease","volume":"99","author":"Liew","year":"2019","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.rmed.2025.108243_bib15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","article-title":"Neutrophil kinetics in health and disease","volume":"31","author":"Summers","year":"2010","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.bj.2020.09.001","article-title":"Understanding the role of neutrophils in acute respiratory distress syndrome","volume":"44","author":"Yang","year":"2021","journal-title":"Biomed. J."},{"issue":"5663","key":"10.1016\/j.rmed.2025.108243_bib17","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.rmed.2025.108243_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1034\/j.1600-065X.2000.917306.x","article-title":"Innate immunity and pulmonary host defense","volume":"173","author":"Zhang","year":"2000","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.rmed.2025.108243_bib19","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1084\/jem.20130056","article-title":"Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow","volume":"210","author":"Devi","year":"2013","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108243_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.rmed.2025.108243_bib21","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1084\/jem.20181468","article-title":"Neutrophils instruct homeostatic and pathological states in naive tissues","volume":"215","author":"Casanova-Acebes","year":"2018","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2016.12.012","article-title":"Neutrophils in homeostasis, immunity, and cancer","volume":"46","author":"Nicol\u00e1s-\u00c1vila","year":"2017","journal-title":"Immunity."},{"key":"10.1016\/j.rmed.2025.108243_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coph.2020.11.003","article-title":"Prospects for COPD treatment","volume":"56","author":"Matera","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.rmed.2025.108243_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/COPD.S10770","article-title":"Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation","volume":"6","author":"Fischer","year":"2011","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108243_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fimmu.2019.00047","article-title":"NETopathic inflammation in chronic obstructive pulmonary disease and severe asthma","volume":"10","author":"Uddin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmed.2025.108243_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/462934","article-title":"Influence of age, past smoking, and disease severity on TLR2, neutrophilic inflammation, and MMP-9 levels in COPD","volume":"2013","author":"Simpson","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.rmed.2025.108243_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3389\/fphar.2017.00512","article-title":"Role of proteases in chronic obstructive pulmonary disease","volume":"8","author":"Pandey","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2025.108243_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1573398X18666220929170117","article-title":"Neutrophil elastase in the pathogenesis of chronic obstructive pulmonary disease: a review","volume":"19","author":"Rosyid","year":"2023","journal-title":"Curr. Respir. Med. Rev."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1373\/clinchem.2016.267450","article-title":"Association of blood eosinophil and blood neutrophil counts with asthma exacerbations in the Copenhagen general population study","volume":"63","author":"Vedel-Krogh","year":"2017","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12931-020-01436-7","article-title":"Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD","volume":"21","author":"Lonergan","year":"2020","journal-title":"Respir. Res."},{"issue":"12","key":"10.1016\/j.rmed.2025.108243_bib31","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.it.2017.07.003","article-title":"Neutrophilic inflammation in asthma and association with disease severity","volume":"38","author":"Ray","year":"2017","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4168\/aair.2022.14.4.361","article-title":"The dynamic contribution of neutrophils in the chronic respiratory diseases","volume":"14","author":"Ham","year":"2022","journal-title":"Allergy Asthma Immunol. Res."},{"key":"10.1016\/j.rmed.2025.108243_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/JAA.S153097","article-title":"Non-eosinophilic asthma: current perspectives","volume":"11","author":"Esteban-Gorgojo","year":"2018","journal-title":"J. Asthma Allergy"},{"issue":"3","key":"10.1016\/j.rmed.2025.108243_bib34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjmed.2021.09.006","article-title":"The use of inhaled corticosteroids for patients with COPD who continue to smoke cigarettes: an evaluation of current practice","volume":"135","author":"Adcock","year":"2022","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108243_bib35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","article-title":"Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease","volume":"131","author":"Barnes","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2025.108243_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108243_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coph.2020.11.003","article-title":"Prospects for COPD treatment","volume":"56","author":"Matera","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"issue":"8","key":"10.1016\/j.rmed.2025.108243_bib38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/17512433.2021.1925537","article-title":"Classes of drugs that target the cellular components of inflammation under clinical development for COPD","volume":"14","author":"Matera","year":"2021","journal-title":"Expet Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.arbres.2023.02.009","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"59","author":"Agust\u00ed","year":"2023","journal-title":"Arch. Bronconeumol."},{"issue":"176","key":"10.1016\/j.rmed.2025.108243_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0179-2024","article-title":"Neutrophilic inflammation in bronchiectasis","volume":"34","author":"Chalmers","year":"2025","journal-title":"Eur. Respir. Rev."},{"issue":"12","key":"10.1016\/j.rmed.2025.108243_bib41","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1111\/all.15505","article-title":"Mechanisms regulating neutrophil responses in immunity, allergy, and autoimmunity","volume":"77","author":"\u00d6zcan","year":"2022","journal-title":"Allergy"},{"issue":"22","key":"10.1016\/j.rmed.2025.108243_bib42","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.3390\/cells12222621","article-title":"Neutrophils in inflammatory diseases: unraveling the impact of their derived molecules and heterogeneity","volume":"12","author":"Riaz","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.rmed.2025.108243_bib43","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2147\/COPD.S419056","article-title":"Novel anti-inflammatory approaches to COPD","volume":"18","author":"Cazzola","year":"2023","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108243_bib44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1183\/09031936.00213711","article-title":"Emerging anti-inflammatory strategies for COPD","volume":"40","author":"Cazzola","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108243_bib45","article-title":"Novel drug discovery strategies for chronic obstructive pulmonary disease: the latest developments","volume":"14","author":"Calzetta","year":"2025","journal-title":"Expet Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/febs.16127","article-title":"Matrix metalloproteinase-13 is fully activated by neutrophil elastase and inactivates its serpin inhibitor, alpha-1 antitrypsin: implications for osteoarthritis","volume":"289","author":"Wilkinson","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.rmed.2025.108243_bib47","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.2147\/COPD.S263725","article-title":"Alpha-1 antitrypsin augmentation therapy improves survival in severely deficient patients with predicted FEV1 between 10% and 60%: a retrospective analysis of the NHLBI alpha-1 antitrypsin deficiency registry","volume":"15","author":"Rahaghi","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108243_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241271917","article-title":"Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series","volume":"18","author":"Aljama","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108243_bib49","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/ijms22031065","article-title":"Protease-specific biomarkers to analyse protease inhibitors for emphysema associated with alpha-1 antitrypsin deficiency. An overview of current approaches","volume":"22","author":"Viglio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.rmed.2025.108243_bib50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/09031936.00173207","article-title":"Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein","volume":"32","author":"Soehnlein","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.rmed.2025.108243_bib51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13543776.2019.1630379","article-title":"A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications","volume":"29","author":"Crocetti","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.rmed.2025.108243_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bcp.2017.02.009","article-title":"Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases","volume":"131","author":"Guarino","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.rmed.2025.108243_bib53","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1021\/acsmedchemlett.9b00261","article-title":"DPP1 inhibitors: exploring the role of water in the S2 pocket of DPP1 with substituted pyrrolidines","volume":"10","author":"K\u00e4ck","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.rmed.2025.108243_bib54","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1111\/bcp.13398","article-title":"Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)","volume":"83","author":"Miller","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib55","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01551-2024","article-title":"Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study","volume":"65","author":"Chalmers","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108243_bib56","article-title":"Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"25","author":"Zhong","year":"2025","journal-title":"Lancet. Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1183\/23120541.00151-2024","article-title":"Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics","volume":"10","author":"Chalmers","year":"2024","journal-title":"ERJ Open Res."},{"issue":"5","key":"10.1016\/j.rmed.2025.108243_bib58","first-page":"359","article-title":"Brensocatib","volume":"46","author":"Cazzola","year":"2021","journal-title":"Drugs Future"},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4300\/JGME-D-22-00480.1","article-title":"Narrative reviews: flexible, rigorous, and practical","volume":"14","author":"Sukhera","year":"2022","journal-title":"J. Grad. Med. Educ."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib60","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","article-title":"Writing narrative style literature reviews","volume":"24","author":"Ferrari","year":"2015","journal-title":"Med. Writ."},{"key":"10.1016\/j.rmed.2025.108243_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1208780","article-title":"The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species","volume":"14","author":"Basso","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"20","key":"10.1016\/j.rmed.2025.108243_bib62","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","article-title":"Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986)","volume":"59","author":"Doyle","year":"2016","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.rmed.2025.108243_bib63","first-page":"34","article-title":"Brensocatib: an anti-neutrophil elastase drug with potential in the management of bronchiectasis","volume":"7","author":"Bowler","year":"2022","journal-title":"US Respir. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108243_bib64","article-title":"Cathepsin C inhibition: a novel approach for the treatment of chronic respiratory diseases [abstract]","volume":"187","author":"Podolin","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108243_bib65","article-title":"Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor [abstract]","volume":"50","author":"Gardiner","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2025.108243_bib66","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cpt.1053","article-title":"Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects","volume":"104","author":"Palmer","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.rmed.2025.108243_bib67","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cpdd.1094","article-title":"Safety, tolerability, and pharmacokinetic evaluation of single and multiple doses of the dipeptidyl peptidase 1 inhibitor brensocatib in healthy Japanese and White adults","volume":"11","author":"Usansky","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib68","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/bcp.16344","article-title":"The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration","volume":"91","author":"Yeung","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"22","key":"10.1016\/j.rmed.2025.108243_bib69","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib70","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1183\/23120541.00505-2024","article-title":"Brensocatib in patients with bronchiectasis: subgroup analyses from the WILLOW trial","volume":"11","author":"Chalmers","year":"2025","journal-title":"ERJ Open Res."},{"issue":"11","key":"10.1016\/j.rmed.2025.108243_bib71","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \"frequent exacerbator phenotype\" in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Respir. Res."},{"issue":"8","key":"10.1016\/j.rmed.2025.108243_bib73","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.ajpath.2014.04.015","article-title":"Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema","volume":"184","author":"Guyot","year":"2014","journal-title":"Am. J. Pathol."},{"issue":"suppl. 64","key":"10.1016\/j.rmed.2025.108243_bib74","first-page":"3328","article-title":"Proteinase-3 as a biomarker of exacerbations in bronchiectasis [abstract]","volume":"56","author":"Abo-Leyah","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.rmed.2025.108243_bib75","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40262-022-01147-w","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of the dipeptidyl peptidase 1 inhibitor brensocatib for non-cystic fibrosis bronchiectasis","volume":"61","author":"Chalmers","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"16","key":"10.1016\/j.rmed.2025.108243_bib76","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108243_bib77","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108243_bib78","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1183\/23120541.00372-2024","article-title":"Heterogeneity in non-cystic fibrosis bronchiectasis: insights from ASPEN trial participants","volume":"10","author":"Ross","year":"2024","journal-title":"ERJ Open Res."},{"issue":"4, Suppl","key":"10.1016\/j.rmed.2025.108243_bib79","doi-asserted-by":"crossref","first-page":"A6554","DOI":"10.1016\/j.chest.2024.07.184","article-title":"Annualized exacerbation rate in patients with non-cystic fibrosis bronchiectasis by prespecified subgroups in the phase 3, randomized, double-blind, placebo-controlled ASPEN trial [abstract]","volume":"166","author":"Metersky","year":"2024","journal-title":"Chest"},{"issue":"4, Suppl","key":"10.1016\/j.rmed.2025.108243_bib80","doi-asserted-by":"crossref","first-page":"A6557","DOI":"10.1016\/j.chest.2024.07.185","article-title":"Lung function in patients with non-cystic fibrosis bronchiectasis by prespecified subgroups in the phase 3, randomized, double-blind, placebo-controlled ASPEN trial [abstract]","volume":"166","author":"Aksamit","year":"2024","journal-title":"Chest"},{"issue":"Suppl 5","key":"10.1016\/j.rmed.2025.108243_bib81","first-page":"A173","article-title":"P112. Efficacy and safety of Dipeptidyl Peptidase-1 (DPP-1) inhibition in long-term macrolide users with bronchiectasis: a post-hoc analysis of the WILLOW trial","volume":"78","author":"Haworth","year":"2023","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2025.108243_bib82","article-title":"A mutation in cathepsin C gene causing papillon-lef\u00e8vre syndrome in a Saudi patient: a case report","volume":"12","author":"Shawli","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.rmed.2025.108243_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1231047","article-title":"Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis","volume":"14","author":"McDonald","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmed.2025.108243_bib84","article-title":"Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-\u03b1-accelerated lupus nephritis in mice","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125003063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125003063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:06:21Z","timestamp":1754258781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125003063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":83,"alternative-id":["S0954611125003063"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108243","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting neutrophilic inflammation in obstructive airway disease - A narrative review of brensocatib therapy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108243"}}